Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET

Core Insights - Mineralys Therapeutics, Inc. is set to announce topline results from its pivotal trials, Launch-HTN and Advance-HTN, on March 10, 2025 [1] Group 1: Company Overview - Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases related to dysregulated aldosterone [5] - The company's lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor [5] Group 2: Trial Details - The Launch-HTN trial assessed the efficacy and safety of lorundrostat as an add-on therapy for uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in patients already on two to five antihypertensive medications [2] - The Advance-HTN trial evaluated lorundrostat's efficacy and safety when used as an add-on therapy for uHTN or rHTN with a standardized background treatment of two or three antihypertensive medications [3]